Short Interest in Certara, Inc. (NASDAQ:CERT) Decreases By 13.9%

Certara, Inc. (NASDAQ:CERT - Get Free Report) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 4,260,000 shares, a drop of 13.9% from the November 30th total of 4,950,000 shares. Currently, 3.8% of the company's shares are sold short. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is presently 3.5 days.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Robert W. Baird reduced their price target on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research report on Tuesday, November 5th. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a report on Friday, September 27th. Finally, Barclays decreased their price objective on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Certara currently has a consensus rating of "Hold" and an average price target of $15.92.

Insider Buying and Selling

In other news, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company's stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Blue Trust Inc. boosted its position in shares of Certara by 112.3% during the third quarter. Blue Trust Inc. now owns 3,925 shares of the company's stock valued at $46,000 after purchasing an additional 2,076 shares in the last quarter. KBC Group NV lifted its position in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after buying an additional 1,584 shares during the period. Intech Investment Management LLC bought a new stake in shares of Certara during the 2nd quarter valued at $152,000. Algert Global LLC purchased a new stake in shares of Certara in the 2nd quarter worth about $156,000. Finally, MQS Management LLC bought a new position in shares of Certara in the 2nd quarter worth about $162,000. Institutional investors own 73.96% of the company's stock.

Certara Trading Up 1.0 %

Certara stock traded up $0.11 during mid-day trading on Tuesday, reaching $10.65. 1,223,939 shares of the company traded hands, compared to its average volume of 850,682. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -53.25, a P/E/G ratio of 5.86 and a beta of 1.53. The firm's 50 day moving average price is $10.73 and its 200 day moving average price is $12.14.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $94.80 million for the quarter, compared to analysts' expectations of $95.51 million. During the same quarter in the previous year, the company earned $0.06 earnings per share. Certara's quarterly revenue was up 10.7% on a year-over-year basis. On average, analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.